What's Going On With Huamacyte Shares Tuesday?
What's Going On With Huamacyte Shares Tuesday?
Humacyte, Inc. (NASDAQ:HUMA) stock is trending on Tuesday. In July, the company has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its Acellular Tissue Engineered Vessel.
周二Humacyte, Inc. (NASDAQ:HUMA)股票上涨。7月，该公司已添加约翰·P·班福思博士和基思·安东尼博士到董事会，签署了与Pluristyx的许可协议，同时获得美国FDA颁发的再生医学高级治疗(RMAT)药物治疗设计ations为其无细胞组织工程血管Vessel。
The Details: Humacyte acquired a license for Pluristyx's PluriBank induced Pluripotent Stem Cell (iPSC) line to use as starting materials in the production of insulin-producing cells for their BioVascular Pancreas (BVP) product candidate.
详情：Humacyte获得了Pluristyx的PluriBank诱导多能干细胞(iPSC)系列的许可以用于生产其生物血管胰腺(BVP)候选产品中的产生胰岛素的细胞的起始材料。
The BVP aims to treat type 1 diabetes by facilitating the delivery and survival of insulin-producing islets within the body.
BVP旨在通过促进胰岛素生产细胞的输送和存活来治疗1型糖尿病。
"The combination of Humacyte's Acellular Tissue Engineered Vessel (ATEV) with insulin-producing cells derived from Pluristyx's best-in-class iPSC lines brings us one step closer to curing insulin dependent diabetes," said Benjamin Fryer, Pluristyx's CEO.
“Humacyte的无细胞组织工程血管和由Pluristyx最佳iPSC系列衍生的产生胰岛素的细胞的组合使我们更接近治愈胰岛素依赖性糖尿病，”Pluristyx首席执行官本杰明·弗莱尔表示。
"We are excited to assist therapeutic developers in using clinical-grade PluriBank iPSC starting materials."
“我们很高兴能帮助治疗性研发人员使用临床级别的PluriBank iPSC起始材料。”
At the start of the month, the company received RMAT designation for the application of Humacyte's ATEV in patients with Advanced Peripheral Artery Disease (PAD). This treatment is particularly beneficial for PAD patients who may not have suitable veins for traditional lower leg bypass procedures.
月初，该公司在Humacyte的无细胞组织工程血管在Advanced Peripheral Artery Disease (PAD)患者中的应用上获得了RMAt药物治疗设计ations。该治疗对于PAD患者尤其有益，因为他们可能没有适合传统下肢搭桥手术的静脉。
The ATEV is an implantable conduit designed for blood vessel replacement and repair. It has demonstrated low infection rates in clinical trials and is readily available off-the-shelf for immediate surgical use.
ATEV是一种可移植的导管，用于血管置换和修复。在临床试验中，感染率低，在医疗机构可立即使用。
Analyst Changes: Multiple analysts have issued price target adjustments throughout July.
分析师变动：多名分析师在7月份发表了对股票的目标价格调整意见。
- BTIG analyst Ryan Zimmerman maintains Humacyte with a Buy and raises the price target from $8 to $11.
- Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte with a Overweight and maintains $7 price target.
- Benchmark analyst Bruce Jackson reiterates Humacyte with a Buy and maintains $15 price target.
- BTIG分析师Ryan Zimmerman 维持Humacyte的买入评级，将目标股价从8美元升至11美元。
- Cantor Fitzgerald的分析师Kristen Kluska重申对Humacyte的看好，维持7美元的目标股价。
- Benchmark的分析师Bruce Jackson重申对Humacyte的买入评级，维持15美元的目标股价。
How To Buy Humacyte Stock
如何购买Humacyte股票
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了手动到经纪所平台购买股票或者部分股票，您还可以通过购买持有股票的ETF，或者在401(k)中分配资金进入一项该类基金或其他工具的策略来获得股票的份额。例如，Coinbase属于金融部门。ETF通常持有许多能跟踪该部门的流动性和大型公司的股票，使投资者能够获得该股票板块内的趋势。
For example, in Humacyte (NASDAQ:HUMA)'s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
例如，在Humacyte (NASDAQ:HUMA)的情况下，它属于医疗保健板块。ETF通常持有许多可以帮助跟踪该板块的流动和大公司的股票，从而使投资者能够获得该领域的趋势。
HUMA Price Action: At the time of publication, Humacyte stock is trading 5.8% higher at $8.89 per data from Benzinga Pro.
HUMA股票走势：截至发布时，Humacyte股票的交易价格为8.89美元，涨幅5.8%。
Image: Michal Jarmoluk from Pixabay
图片：来自Pixabay的Michal Jarmoluk